Yang Song1, Ming Yang1, Hongjian Zhang1, Yan Sun2, Ye Tao3, Huihui Li4, Jing Zhang1, Yuncheng Li5, Jianming Yang1. 1. Department of Otorhinolaryngology, The Second Hospital of Anhui Medical University, Hefei, Anhui 230601, China. 2. Department of Otorhinolaryngology and Head and Neck Surgery, Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China. 3. Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing 100730, China. 4. Physical Examination Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. 5. Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Abstract
BACKGROUND: Cytokines play important roles in the development and prognosis of laryngeal cancer (LC). Interleukin-17 (IL-17) from a distinct subset of CD4+ T cells may significantly induce cancer-elicited inflammation to prevent tumor immune surveillance. METHODS: The expression levels of IL-17 were examined among 60 patients with LC. Immunofluorescence colocalization experiments were performed to verify the localization of IL-17 and FAS/FASL in Hep-2 and Tu212 cells. The role of IL-17 was determined using siRNA techniques in the LC cell line. RESULTS: In the LC patients, cytokines were dysregulated in LC tissues compared with normal tissues. It was found that IL-17 was overexpressed in a cohort of 60 LC tumors paired with nontumor tissues. Moreover, high IL-17 expression was significantly associated with the advanced T category, the late clinical stage, differentiation, lymph node metastasis, and recurrence. In addition, the time course expression of FAS and FASL was observed after stimulation and treatment with the IL-17 stimulator. Finally, in vitro experiments demonstrated that IL-17 functioned as an oncogene by inhibiting the apoptosis of LC cells via the PI3K/AKT/FAS/FASL pathways. CONCLUSIONS: In summary, these findings demonstrated for the first time the role of IL-17 as a tumor promoter and a prometastatic factor in LC and indicated that IL-17 may have an oncogenic role and serve as a potential prognostic biomarker and therapeutic target in LC.
BACKGROUND: Cytokines play important roles in the development and prognosis of laryngeal cancer (LC). Interleukin-17 (IL-17) from a distinct subset of CD4+ T cells may significantly induce cancer-elicited inflammation to prevent tumor immune surveillance. METHODS: The expression levels of IL-17 were examined among 60 patients with LC. Immunofluorescence colocalization experiments were performed to verify the localization of IL-17 and FAS/FASL in Hep-2 and Tu212 cells. The role of IL-17 was determined using siRNA techniques in the LC cell line. RESULTS: In the LC patients, cytokines were dysregulated in LC tissues compared with normal tissues. It was found that IL-17 was overexpressed in a cohort of 60 LC tumors paired with nontumor tissues. Moreover, high IL-17 expression was significantly associated with the advanced T category, the late clinical stage, differentiation, lymph node metastasis, and recurrence. In addition, the time course expression of FAS and FASL was observed after stimulation and treatment with the IL-17 stimulator. Finally, in vitro experiments demonstrated that IL-17 functioned as an oncogene by inhibiting the apoptosis of LC cells via the PI3K/AKT/FAS/FASL pathways. CONCLUSIONS: In summary, these findings demonstrated for the first time the role of IL-17 as a tumor promoter and a prometastatic factor in LC and indicated that IL-17 may have an oncogenic role and serve as a potential prognostic biomarker and therapeutic target in LC.
Authors: Scott M Tanner; Joseph G Daft; Stephanie A Hill; Colin A Martin; Robin G Lorenz Journal: J Histochem Cytochem Date: 2016-10-20 Impact factor: 2.479
Authors: Muhammet Fatih Topuz; Adem Binnetoglu; Ali Cemal Yumusakhuylu; Murat Sarı; Tekin Baglam; Fetullah Gerin Journal: Eur Arch Otorhinolaryngol Date: 2017-03-01 Impact factor: 2.503
Authors: Michał Jarocki; Julia Karska; Szymon Kowalski; Paweł Kiełb; Łukasz Nowak; Wojciech Krajewski; Jolanta Saczko; Julita Kulbacka; Tomasz Szydełko; Bartosz Małkiewicz Journal: J Clin Med Date: 2022-08-24 Impact factor: 4.964